Visual Acuity as an Outcome Measure in Clinical Trials of Retinal Diseases
- 1 October 2007
- journal article
- Published by Elsevier in Ophthalmology
- Vol. 114 (10) , 1804-1809
- https://doi.org/10.1016/j.ophtha.2007.06.047
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Pegaptanib for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2004
- A computerized method of visual acuity testing: Adaptation of the early treatment of diabetic retinopathy study testing protocolPublished by Elsevier ,2003
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2American Journal of Ophthalmology, 2001
- Robustness of the t Test Applied to Data Distorted from Normality by Floor EffectsJournal of Dental Research, 1992
- REPRODUCIBILITY OF REFRACTION AND VISUAL ACUITY MEASUREMENT UNDER A STANDARD PROTOCOLRetina, 1989
- Photocoagulation for Diabetic Macular EdemaArchives of Ophthalmology (1950), 1985
- New Visual Acuity Charts for Clinical ResearchAmerican Journal of Ophthalmology, 1982
- Argon Laser Photocoagulation for Senile Macular DegenerationArchives of Ophthalmology (1950), 1982